Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-11-21
2006-11-21
Minnifield, Nitta (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S145100, C424S085500, C424S085200, C424S134100, C424S141100, C424S178100, C514S002600, C514S825000, C514S866000, C514S903000, C530S388100, C530S387100, C530S388230, C530S389200, C530S389100
Reexamination Certificate
active
07138115
ABSTRACT:
Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
REFERENCES:
patent: 5536657 (1996-07-01), Chua et al.
patent: 5547852 (1996-08-01), Seiler et al.
patent: 5650492 (1997-07-01), Gately et al.
patent: 5853721 (1998-12-01), Gately et al.
patent: 6054487 (2000-04-01), Sekut et al.
patent: 6225117 (2001-05-01), Gately et al.
patent: 6338848 (2002-01-01), Leonard et al.
patent: 6706264 (2004-03-01), Leonard et al.
patent: 6830751 (2004-12-01), Leonard et al.
patent: 7026456 (2006-04-01), Gately et al.
patent: 7063964 (2006-06-01), Giles-Komar et al.
patent: 2002/0194631 (2002-12-01), Ehrhardt et al.
patent: 2003/0021763 (2003-01-01), Germann et al.
patent: 2003/0162261 (2003-08-01), Oppmann et al.
patent: 2003/0228311 (2003-12-01), Strober et al.
patent: 2004/0156849 (2004-08-01), Gurney
patent: 2004/0161747 (2004-08-01), Morahan
patent: 2005/0079177 (2005-04-01), Leonard et al.
patent: 2123049 (1999-11-01), None
patent: 43 15 127.2 (1993-11-01), None
patent: 0 433 827 (1991-06-01), None
patent: 0 625 354 (1994-11-01), None
patent: 0 638 644 (1995-02-01), None
patent: 0 640 689 (1995-03-01), None
patent: 406329549 (1994-11-01), None
patent: WO 92/05256 (1992-04-01), None
patent: WO 93/19770 (1993-10-01), None
patent: WO 98/16248 (1998-04-01), None
patent: WO 98/22137 (1998-05-01), None
patent: WO 98/41232 (1998-09-01), None
patent: WO 99/36073 (1999-07-01), None
patent: WO 99/37682 (1999-07-01), None
Adorini, J. Neurological Sciences, 2004, 223:13-24.
Tarner et al, Current Opinion in Immunology, 2001, 13:676-682.
MacDonald et al, TRENDS in Immunology, 2001, 22/5:244-247.
Karp et al, Immunology Today, Jan. 2000, 21/1:24-28.
Falcone et al, Current Opinion in Immunology, 1999, 11:670-676.
Okamura et al, Current Opinion in Immunology, 1998, 10:259-264.
Stern et al, Life Sciences, 1996, 58/8:639-654.
Trinchieri et al, Immunity, 2003, 19:641-644.
Costa et al, J. Immunology, 2001, 167:2379-2387.
Li et al, J. Neurological Sciences, 2003, 215:95-103.
Yadav et al, Current Opinion in Immunology, 2003, 15:697-703.
Weiner, J. Neurological Sciences, 2004, 223:1-11.
Jander et al, J. Neuroimmunology, 1998, 91:93-99.
Leiro et al, International Immunopharmacology, 2004, 4:763-778.
Kim et al, Immunity, Jan. 2005, 22:131-142.
Kang et al, Cellular Signalling, 2005, 17:665-673.
Campbell et al, J. Clin. Invest., 1991, 87:739-742.
Baeder et al, Clin. Exp. Immunol., 1992, 89:174-178.
Charteris et al, Immunology, 1992, 75:463-467.
Kai et al, Transplantation, Apr. 1993, 55/4:936-940.
Knoerzer et al, J. Clin. Invest., 1995, 96:987-993.
Merino et al, J. Exp. Med., Oct. 1993, 178:1189-1197.
Tang et al, Eur. J. Immunol., 1993, 23:275-278.
Derwent Abstract, WPI Acc No. 1994-350242, DE 4315127.2, Germany.
Kelso, et al., “Heterogeneity in Lymphokine Profiles of CD4+ and CD8+ T Cells and Clones Activatedin vivoandin vitro” Immunological Reviews, 123:85-114 (1991).
Arnaudova et al., Application of Interferon-γ Containing Gel for Local Treatment of Skin Ulcers in Autoimmune Vasculitides and Skin Changes in Progressive Systemic Sclerosis,The Journal of Rheumatology, 20:1445-1446 (1993).
Bach, Immunosuppressive Therapy of Autoimmune Diseases,Immunology Today, 14:322-326 (1993).
Bach, Immunosuppressive Therapy of Autoimmune Diseases,Trends in Pharmacological Sciences, 14:213-216 (1993).
Balashov et al., Increased Interleukin 12 Production in Progressive Multiple Sclerosis: Induction by Activated CD4+T Cells Via CD40 Ligand,Proceedings of the National Academy of Sciences U.S.A., 94:599-603 (1997).
Bankhurst, Interferons and SystemicLupus erythematosus, Journal of Rheumatology, 14:63-67 (1987).
Baron et al., Production of Tumor Necrosis Factor and Other Proinflammatory Cytokines by Human Mononuclear Phagocytes Stimulated with Myelin P2 Protein,Proceedings of the National Academy of Sciences U.S.A., 90:4414-4418 (1993).
Baron et al., Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma,Journal of Experimental Medicine, 177:57-68 (1993).
Becher et al., Experimental Autoimmune Encephalitis and Inflammation in the Absence of Interleukin-12,Journal of Clinical Investigation, 110(4):493-497 (2002).
Borigini et al., Combination Therapy,Bailliere's Clinical Rheumatology9:689-710 (1995).
Butler et al., Anti-IL-12 and Anti-TNF Antibodies Synergistically Suppress the Progression of Murine Collagen-Induced Arthritis,European Journal of Immunology, 29:2205-2212 (1999).
Campbell et al., Essential Role for Interferon-γ and Interleukin-6 in Autoimmune Insulin-Dependent Diabetes in NOD/Wehi Mice,Journal of Clinical Investigation, 87:739-742 (1991).
Castaño et al., Type-I Diabetes: A Chronic Autoimmune Disease of Human, Mouse, and Rat,Annual Review of Immunology, 8:647-679 (1990).
Chan et al., Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers,Journal of Experimental Medicine, 173:869-879 (1991).
Charteris et al., Interferon-Gamma (IFN-γ) ProductionIn Vivoin Experimental Autoimmune Uveoretinitis,Immunology, 75:463-467 (1992).
Chizzonite et al., IL-12 Receptor I. Characterization of the Receptor on Phytohemagglutinin-Activated Human Lymphoblasts,The Journal of Immunology, 148:3117-3124 (1992).
Chizzonite et al., IL-12: Monoclonal Antibodies Specific for the 40-kDa Subunit Block Receptor Binding and Biologic Activity on Activated Human Lymphoblasts,The Journal of Immunology, 147:1548-1556 (1991).
Chofflon et al., Tumor Necrosis Factor α Production as a Possible Predictor of Relapse in Patients with Multiple Sclerosis,European Cytokine Network, 3:523-531 (1992).
Chua et al., Expression Cloning of a Human IL-12 Receptor Component: A New Member of the Cytokine Receptor Superfamily with Strong Homology to gp130,The Journal of Immunology, 153:128-136 (1994).
Constantinescu et al., IL-12 Reverses the Suppressive Effect of the CD40 Ligand Blockade on Experimental Autoimmune Encephalomyelitis (EAE),Journal of the Neurological Sciences, 171:60-64 (1999).
Duchmann et al., Interleukin-12 mRNA is Induced in Lamina Propria Mononuclear Cells from Patients with Inflammatory Bowel Disease (IBD),Gastroenterology(Suppl.), 104:A693 (1993).
Feldmann et al., Evaluation of the Role of Cytokines in Autoimmune Disease: The Importance of TNFα in Rheumatoid Arthritis,Progress in Growth Factor Research, 4:247-255 (1992).
Fox et al., Anti-Interleukin-12 Antibody: Potential Role in Preventing Relapses of Multiple Sclerosis,BioDrugs, 13:233-241 (2000).
Fujihira et al., Suppression and Acceleration of Autoimmune Diabetes by Neutralization of Endogenous Interleukin-12 in NOD Mice,Diabetes, 49:1998-2006 (2000).
Funauchi et al., Serum Level of Interferon-γ in Autoimmune Diseases,Tohoku Journal of Experimental Medicine, 164:259-267 (1991).
Fuss et al., Disparate CD4+Lamina Propria (LP) Lymphokine Secretion Profiles in Inflammatory Bowel Disease,The Journal of Immunology, 157(3):1261-1270 (1996).
Gately et al., Interleukin-12 Antagonist Activity of Mouse Interleukin-12 p40 Homodimerin Vitroandin Vivo, Annals of New York Academy of Sciences, 795:1-12 (1996).
Germann et al., IL-12, a Cytokine with Multiple Effects on TH1-, but not on TH2-cells,Immunobiology, 186:38 (1992).
Germann et al., Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice,Proceedings of the National Academy of Sciences U.S.A., 92:4823-4827 (1995).
Godfrey et al., A Developmental Pathway Involving Four Phenotypically and Functionally Distinct Subsets of CD3-CD
Goldman Samuel
Leonard John P.
O'Hara, Jr. Richard
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Genetics Institute LLC
Minnifield Nitta
LandOfFree
Use of IL-12 and IL-12 antagonists in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of IL-12 and IL-12 antagonists in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of IL-12 and IL-12 antagonists in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3677442